Aurobindo watermark

Mission

Add value through superior customer service in the distribution of a broad line of generic pharmaceuticals, leveraging vertical integration and efficient controlled processes.

Vision

To become a consistent top 10 generic pharmaceutical supplier with a reputation for superior customer service, honesty and transparency.

Core Values & Behaviors

  • icon-person

    Customer Care

    Customer satisfaction is paramount to our success

    • Understand our business, our industry, and what is important to our customers; stay current and informed. Anticipate and understand the impact of our actions on the customer
    • Strive for 100% accuracy in all customer-related activities including orders, shipments, and correspondence
    • Establish long-term relationships with customers based on integrity and trust
    • Actively seek and utilize customer feedback
    • Responsive to customer complaints and inquiries

  • icon-people

    People Care

    Our people are what makes APUSA. We will continuously develop and grow our employees

    • Foster relationships with fellow employees so they are proud to be part of APUSA
    • Be transparent in communications. Encourage employee feedback and contribution
    • Respect fellow employees. Treat others as you would want to be treated
    • Recognize others who make a  significant contribution to the business

  • icon-doc

    Business Care

    Our business will meet or exceed the expectations of our customers

    • Focus on the long term health of the company vs. short-term gains
    • Challenge the status quo, suggest new and different ways to improve the business
    • Design and implement systems and processes from the customer’s perspective
    • Seek to attain the highest quality standards
    • Accept accountability for one’s actions

Our Story | Aurobindo Through the Years

Creation of a leading vertically integrated platform

Major Milestones

  • icon-vial

    Consolidating Presence in US and EU + Expanding Injectables & Differentiated Offerings

  • icon-globe

    Establishing Global Footprint

  • icon-dose

    Foray into Finished Dosage Formulations

  • icon-gears

    API Focus

Historical Timeline

2017

  • Opened 565,000 sq. ft. fully automated state-of-art distribution center in East Windsor, NJ
  • Opened a new, 40,000 sq. ft. specialty pharma R&D facility in Durham, NC
  • APL acquired 4 cell culture-derived biosimilar products from Swiss TL Biopharmaceutical. Three out of the four biosimilars are monoclonal antibodies in oncology.
  • APL acquires Portugal’s Generis Farmaceutica SA

2016

  • Aurobindo Pharma USA, Inc. moves Corporate Headquarters to East Windsor, NJ, USA

2015

  • Investment into Tergene to fund the development of a pneumonia vaccine

2014

  • Aurobindo Pharma USA, Inc. acquires Natrol Inc. in California, USA
  • Aurohealth LLC begins doing business in Lawrenceville, NJ, USA
  • Focus on differentiated technology platforms eg. depot injections
  • APL acquires commercial operations in Western Europe from Actavis making it one of the leading Indian pharmaceutical companies in Europe.

2013

  • Commenced marketing specialty injectables to fund the development in USA through AuroMedics
  • Building capabilities in Penem, Oncology & Biocatalysis

2012

  • First approval of Controlled Substance formulations in USA
  • Set up AuroPeptide to foray into peptide business
  • Aurohealth LLC, our OTC division becomes an entity

2011

  • AuroMedics Pharma LLC begins selling and distributing Injectables in the USA

2010

  • Commenced operations of SEZ Unit VII and Aurolife, USA facilities and divested Chinese antibiotics products facility

2008

  • Aurolife Pharma LLC begins manufacturing solid oral dose.

2007

  • Acquired formulations facility in USA
  • Investment in building manufacturing, marketing & IPR capabilities

2006

  • Acquired building from Sandoz to begin Aurolife Manufacturing in Dayton, NJ, USA

2004

  • Aurobindo Pharma USA, Inc. becomes incorporated in USA

1992-2002

  • Commencement of export of APIs
  • Initial Public Offering (1995)
  • Began production of formulations